Literature DB >> 24581579

Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists.

Hortensia Ferrero1, Carmen M García-Pascual1, Raúl Gómez2, Francisco Delgado-Rosas3, Omar Cauli4, Carlos Simón1, Francisco Gaytán5, Antonio Pellicer1.   

Abstract

OBJECTIVE: To ascertain whether vascular endothelial growth factor (VEGF) secretion by luteinized granulosa cells (GCs) is modulated by the dopaminergic system in a dose-dependent fashion and how this is related to the differential efficacy of dopamine receptor 2 (D2)-agonists (D2-ag) in preventing ovarian hyperstimulation syndrome (OHSS).
DESIGN: The relationship between the dopaminergic system and VEGF secretion in luteinized GCs was evaluated. Archived human ovaries were immunostained to characterize D2 expression.
SETTING: University affiliated infertility center. PATIENT(S): Premenopausal women and egg donors. INTERVENTION(S): Luteinized GCs were cultured with the D2-ag cabergoline. Human ovarian sections were immunostained for D2. MAIN OUTCOME MEASURE(S): The VEGF was measured by ELISA and D2 expression was evaluated by In-Cell ELISA. The D2 expression throughout the luteal phase was characterized by immunohistochemistry. RESULT(S): The VEGF secretion was decreased by the D2-ag in a dose-dependent fashion. The efficiency of this process was correlated with the amount of D2 expressed by luteinized GCs. A decrease in D2 expression in ovarian sections was observed during the late luteal phase. CONCLUSION(S): The efficacy of D2-ags in preventing OHSS might rely on their capacity to inhibit VEGF secretion by luteinized GCs. Because this capacity is dose-dependent, increasing the intraovarian concentration of D2-ags should be explored as a means of increasing the efficacy of these drugs in preventing OHSS.
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  OHSS; VEGF; dopamine receptor 2; dopamine receptor 2 agonist; granulosa cells

Mesh:

Substances:

Year:  2014        PMID: 24581579     DOI: 10.1016/j.fertnstert.2014.01.031

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  4 in total

1.  THE ROLE OF HIGH FOLLICULAR LEVELS OF ANGIOTENSIN II AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN ANTICIPATING THE DEVELOPMENT OF SEVERE OVARIAN HYPERSTIMULATION SYNDROME IN PATIENTS WITH PROPHYLACTIC CABERGOLINE THERAPY UNDERGOING AN IN VITRO FERTILIZATION PROCEDURE.

Authors:  M Surcel; M Surcel; C Zlatescu-Marton; R Micu; G I Nemeti; D D Axente; C Mirza; I Neamtiu
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

2.  Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells.

Authors:  Hortensia Ferrero; Carmen M García-Pascual; Nuria Pellicer; Carlos Simón; Antonio Pellicer; Raúl Gómez
Journal:  Reprod Biol Endocrinol       Date:  2015-09-17       Impact factor: 5.211

3.  Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.

Authors:  Niyazi Kılıç; Özhan Özdemir; Hakan Cevdet Başar; Fadime Demircan; Fırat Ekmez; Oğuz Yücel
Journal:  Avicenna J Med       Date:  2015 Oct-Dec

4.  The Inhibitory Effect of Selected D2 Dopaminergic Receptor Agonists on VEGF-Dependent Neovascularization in Zebrafish Larvae: Potential New Therapy in Ophthalmic Diseases.

Authors:  Natalia Kasica; Anna Święch; Katarzyna Saładziak; Jerzy Mackiewicz; Maciej Osęka
Journal:  Cells       Date:  2022-04-02       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.